Navigation Links
ChemoCentryx Advances Second Orally Available CCR9 Antagonist CCX025 Into Clinical Development
Date:10/15/2008

Solidifies Company's Leadership Position in Targeting Chemokine Receptor

CCR9 for Gastrointestinal Diseases

MOUNTAIN VIEW, Calif., Oct. 15 /PRNewswire/ -- ChemoCentryx, Inc., announced today that it has initiated a Phase I clinical trial of CCX025, the company's fourth investigational new drug and second orally administered compound that inhibits the chemokine receptor known as CCR9. Structurally distinct from Traficet-EN(TM) (CCX282-B; ChemoCentryx's CCR9 antagonist currently in a Phase II/III clinical trial for Crohn's disease), CCX025 strengthens ChemoCentryx's position in the CCR9 arena and expands the company's gastrointestinal franchise with the potential to pursue different clinical indications with discrete compounds.

"With the advancement of CCX025 into the clinic, ChemoCentryx can pursue a greater breadth of diseases associated with CCR9 receptor inhibition with the clear advantage of having two structurally distinct, very potent and highly-selective oral therapeutics," said Thomas J. Schall, Ph.D., President and Chief Executive Officer of ChemoCentryx. "CCX025 is our fourth product candidate in the clinic, all discovered and developed at ChemoCentryx, and establishes our position as a leader in the industry in developing chemokine-based therapeutics."

The Phase I double-blind, placebo-controlled trial of CCX025 is being conducted in healthy male and female volunteers to evaluate the safety, tolerability and pharmacokinetics of CCX025 over a range of dose levels. In preclinical studies, the compound has been shown to be well-tolerated and highly selective. Like Traficet-EN, CCX025 is differentiated from existing inflammatory bowel disease therapies such as biologics (which are typically injected or infused), steroids and immunosuppressives and may offer a novel, safe and conveniently administered treatment option.

CCX025 and Traficet-EN are oral, highly-specific inhibitors of the chemokine receptor kn
'/>"/>

SOURCE ChemoCentryx, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. ChemoCentryx Demonstrates Recently Discovered Chemokine Receptor CXCR7 is Essential in Tumor Growth
2. Will New Technological Advances Offer Fresh Capabilities for Commercialization and Enhance BTL Investments?
3. Ardea Biosciences Advances RDEA806 Into Phase 2a Proof-of-Concept Study for Gout
4. New molecular imaging techniques may lead to advances in disease treatment
5. Pharmacopeia Advances Strategic Plan to Focus Resources on Development and Later-Stage Discovery Programs
6. Regenesis Biomedical Advances Corporate Strategy by Appointing Vice President of Marketing
7. Sirion Therapeutics Preclinical Studies: Two New Potential Advances in Treatment of Retinal Diseases to be Presented at ARVO
8. Human Genome Sciences Advances Oncology Portfolio
9. ITSSD: Russia Can Secure Greatest Biotech Market Advances Following US, Not EU Innovation Model
10. Genetic Engineering & Biotechnology News reports on advances in miRNA
11. Malaysia Genome Institute Advances Bioinformatics Research Using SGI Technology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)... MADRID , Nov. 26, 2014 ... presented results from a survey of European physicians ... Meeting on Innovation and Biological Therapies" at the ... The event, hosted by EuropaBio and the Spanish ... Ministry of Health, physicians from Spanish oncology and ...
(Date:11/26/2014)... November 26, 2014 The ETC ... award-winning technology innovation centers, announced today that applications ... on December 1st. “Do you have a big ... I want to know about it. AccelerateBaltimore helps ... to product in just 13 weeks.” Interested ...
(Date:11/26/2014)... November 25, 2014 Whitehouse Laboratories ... joined the Morris County (New Jersey) Chamber of ... a leading business organization in the North Jersey ... further engage some key clients in the pharmaceutical ... the geographic area. Membership enables Whitehouse Laboratories a ...
(Date:11/26/2014)... November 25, 2014 Silicon Valley Electronic ... with RPM Alliance , provider of clinical research ... With the latest addition to its CRO Partnership Program, ... EDC system to India. , “We have found ... and customizable EDC platform which is both user friendly ...
Breaking Biology Technology:ASBM Presents European Physicians Survey at Spanish Ministry of Health 2AccelerateBaltimore Applications to Close in 6 Days 2AccelerateBaltimore Applications to Close in 6 Days 3Whitehouse Laboratories Joins Morris County Chamber of Commerce 2Whitehouse Laboratories Joins Morris County Chamber of Commerce 3RPM Alliance Joins Clinovo’s CRO Partnership Program, Further Strengthening Its Presence in Southern California and India 2
... president and CEO Michael J. Collins delivered the commencement address ... Department, which was held on May 18, 2012. Collins received ... been a member of the Advisory Board for the Chemistry ... (Logo: http://photos.prnewswire.com/prnh/20090622/CL35336LOGO-b ) "I am ...
... one in four adults suffering from a diagnosable ... high case loads, the value of independent living ... effective mental health services. ILCs are generally thought ... physical disabilities, but across the country, directors and ...
... 24, 2012  Novocure™, a commercial stage private oncology company, ... of excellence will join the seven existing clinical centers ... patients with recurrent GBM. These fifteen clinical centers are ... GBM is both the deadliest and most ...
Cached Biology Technology:CEM President and CEO Delivers Commencement Address at the 2012 University of Texas at Austin Chemistry and Biochemistry Department Graduation 2Peers Underscored As An Effective Counseling Tool 2Novocure™ Certifies Eight Additional Clinical Centers of Excellence to Treat Most Common Brain Tumor with Tumor Treating Fields (TTFields) Therapy 2Novocure™ Certifies Eight Additional Clinical Centers of Excellence to Treat Most Common Brain Tumor with Tumor Treating Fields (TTFields) Therapy 3Novocure™ Certifies Eight Additional Clinical Centers of Excellence to Treat Most Common Brain Tumor with Tumor Treating Fields (TTFields) Therapy 4
(Date:11/11/2014)... , Nov. 11, 2014  Forensicon, Inc., a ... is pleased to announce the promotion of Yaniv ... of Digital Forensics. In Schiff,s new role as Director, ... team of digital forensics examiners and provide leadership within ... Photo - http://photos.prnewswire.com/prnh/20141110/157719 Schiff ...
(Date:11/6/2014)... paper from a team of Florida State University biologists ... could adapt to and survive environmental swings such as ... latest issue of the journal The Plant Cell ... DNA and proteins) is organized in a cell and ... are turned on and others are turned off. , ...
(Date:11/5/2014)... RENO – Kelly Redmond has dedicated his career ... knowledge to a general audience. , As deputy ... Climate Center at Nevada,s Desert Research Institute, Redmond ... the management, application and dissemination of climate data ... Annual Fall Meeting in San Francisco on December ...
Breaking Biology News(10 mins):Yaniv Schiff Promoted to Director of Digital Forensics at Forensicon, Inc. 2Maize analysis yields whole new world of genetic science 2Nevada climatologist to be honored at AGU Fall Meeting for lifetime of public outreach 2
... Three-day-old broccoli sprouts, a widely available human food, suppressed ... a report in Cancer Prevention Research , a journal ... pylori infections are one of the most common bacterial ... The cancer protective effects of sulforaphane, a phytochemical ...
... As the U.S. Southwest grew warmer from 18,700 to ... the Mojave Desert, robbing packrats of their favorite food. Now, ... genes that let the rodents eat toxic creosote bushes that ... out," says biology Professor Denise Dearing, senior author of the ...
... for Kids" event on April 18 at Pembroke ... Va., April 2 Turner Network Sales (TNS), ... Inc. (TBS, Inc.), and truTV, are partnering with Cox Communications ... "Digital Fingerprinting for Kids" event , a service designed to ...
Cached Biology News:Poison: It's what's for dinner 2Poison: It's what's for dinner 3Poison: It's what's for dinner 4Poison: It's what's for dinner 5truTV and Cox Offer Free Digital Fingerprinting to Help Prevent Crimes Against Children 2truTV and Cox Offer Free Digital Fingerprinting to Help Prevent Crimes Against Children 3
... bovine, porcine, rat) ... antagonist. This carboxy-terminal VIP fragment ... more potent than any previously ... Storage: Desiccate ...
Protein 3D structure prediction, via threading. Easy to use....
L1 Protein of Human Papilloma Virus Purified Anti-Viral-transformed cells clone CAMVIR-1, Isotype Mouse IgG 2a , 0.1 mg Consult technical datasheet for details....
ANTI 5-HYDROXYTRYPTOPHAN CONJ....
Biology Products: